Notably, our analysis of these clinical samples revealed more interactions between KAT6A and PARP1 in PARPi‐resistant ovarian tumors than in primary ovarian cancer (Figure 1C,E), suggesting a potential role of KAT6A in PARPi resistance. Here, KAT6A is linked to ovarian neoplasm.